Form 4: Labcorp Director Davis Acquires 773 Restricted Stock Units

Labcorp Holdings Inc. Director Jeffrey A. Davis acquired 773 Restricted Stock Units, bringing his total beneficial ownership to 1,670 RSUs.

Summary

• Jeffrey A. Davis, a Director of Labcorp Holdings Inc. (LH), acquired 773 Restricted Stock Units (RSUs).
• The transaction occurred on February 10, 2026.
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• These 773 RSUs will vest fully on February 10, 2027.
• Following this acquisition, Davis beneficially owns an aggregate of 1,670 Restricted Stock Units.
• The filing was signed by Kathryn W. Kyle, Attorney-in-Fact for Jeffrey A. Davis, on February 12, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates a director's continued equity accumulation, aligning their interests with long-term company performance, which is generally favorable for shareholders.

Positives

• Director Jeffrey A. Davis increased his beneficial ownership in Labcorp Holdings Inc. by acquiring 773 Restricted Stock Units.
• The acquisition of RSUs aligns the director's interests with long-term shareholder value.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4. The inherent risk of equity ownership applies.

Future Outlook

The filing indicates a future vesting event for the acquired Restricted Stock Units on February 10, 2027, aligning a portion of director compensation with future company performance.

Management Comments

• Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The Restricted Stock Units vest fully on February 10, 2027.
• This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive and director compensation in the healthcare diagnostics and life sciences industry, aligning leadership incentives with long-term shareholder value. This grant is consistent with typical compensation practices for directors in publicly traded companies of Labcorp's size and market position.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is a standard practice in corporate governance across industries, including healthcare and diagnostics, similar to companies like Quest Diagnostics (DGX) or Charles River Laboratories (CRL).
• The vesting schedule, a single full vest after one year, is a common structure for director equity awards, designed to retain directors and incentivize sustained performance.

Stakeholder Impact

• Shareholders: The acquisition of additional equity by a director generally signals confidence in the company's future and aligns management interests with shareholder returns.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• The 773 Restricted Stock Units are scheduled to vest fully on February 10, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director as part of their compensation. While it indicates continued alignment of interests, it does not present new information significant enough to warrant a change in investment recommendation based solely on this filing. It's a standard operational event for a publicly traded company.

Keywords

Labcorp Holdings Inc., LH, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Jeffrey A. Davis, Equity Grant